← Back to Search

Anti-metabolites

pemetrexed for Cancer

Phase 2
Waitlist Available
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up blood and tissue from baseline, then additional blood every 6 weeks while on treatment
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial is studying pemetrexed disodium to see how well it works in treating patients with recurrent malignant gliomas, primary CNS lymphoma, or brain metastases.

Eligible Conditions
  • Cancer
  • Brain Tumor
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~blood and tissue from baseline, then additional blood every 6 weeks while on treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and blood and tissue from baseline, then additional blood every 6 weeks while on treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Compare blood and tissue methylation patterns and correlate with response.

Side effects data

From 2022 Phase 3 trial • 1274 Patients • NCT02220894
12%
Weight decreased
9%
Constipation
9%
Bronchitis
9%
Haemoptysis
9%
Aspartate aminotransferase increased
9%
Diarrhoea
9%
Decreased appetite
9%
Arthralgia
9%
Nasopharyngitis
9%
Alanine aminotransferase increased
9%
Hypothyroidism
6%
Headache
6%
Anaemia
6%
Cough
6%
Pruritus
6%
Asthenia
6%
Blood alkaline phosphatase increased
6%
Pneumonia
3%
Back pain
3%
Tumour associated fever
3%
Subdural haemorrhage
3%
Dyspnoea
3%
Upper respiratory tract infection
3%
Leukopenia
3%
Nausea
3%
Pyrexia
3%
Lymph gland infection
3%
Hyperglycaemia
3%
Malaise
3%
Rash
3%
Oedema peripheral
3%
Myalgia
3%
Upper gastrointestinal haemorrhage
3%
Chest pain
3%
White blood cell count decreased
3%
Hypertension
3%
Haematemesis
3%
Pneumonia bacterial
3%
Hyperthyroidism
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pembrolizumab Second Course
Pembrolizumab
Chemotherapy (SOC Treatment)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
Pemetrexed 900 mg/m2 every 21 days until disease progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,906 Previous Clinical Trials
41,012,001 Total Patients Enrolled
Northwestern UniversityLead Sponsor
1,640 Previous Clinical Trials
957,541 Total Patients Enrolled
Jeffrey J. Raizer, MDStudy ChairRobert H. Lurie Cancer Center
8 Previous Clinical Trials
210 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top